X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (50797) 50797
Newsletter (1122) 1122
Newspaper Article (212) 212
Dissertation (186) 186
Book Chapter (115) 115
Conference Proceeding (61) 61
Magazine Article (45) 45
Publication (33) 33
Government Document (31) 31
Book / eBook (13) 13
Streaming Video (13) 13
Transcript (10) 10
Web Resource (8) 8
Book Review (6) 6
Reference (4) 4
Paper (2) 2
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (32059) 32059
paclitaxel (31863) 31863
female (20561) 20561
oncology (18792) 18792
chemotherapy (13961) 13961
middle aged (12647) 12647
cancer (12571) 12571
paclitaxel - administration & dosage (12454) 12454
aged (11136) 11136
male (10707) 10707
animals (9268) 9268
antineoplastic combined chemotherapy protocols - therapeutic use (9173) 9173
adult (8820) 8820
paclitaxel - pharmacology (7209) 7209
treatment outcome (7083) 7083
pharmacology & pharmacy (6565) 6565
cisplatin (5678) 5678
cell line, tumor (5584) 5584
paclitaxel - therapeutic use (5178) 5178
mice (4971) 4971
breast neoplasms - drug therapy (4933) 4933
breast cancer (4846) 4846
taxol (4834) 4834
research (4539) 4539
carboplatin (4463) 4463
care and treatment (4430) 4430
therapy (4206) 4206
apoptosis (4190) 4190
docetaxel (4143) 4143
paclitaxel - adverse effects (3852) 3852
lung neoplasms - drug therapy (3838) 3838
nanoparticles (3836) 3836
ovarian neoplasms - drug therapy (3794) 3794
carcinoma (3703) 3703
ovarian cancer (3657) 3657
analysis (3638) 3638
trial (3597) 3597
antineoplastic combined chemotherapy protocols - adverse effects (3583) 3583
tumors (3370) 3370
carboplatin - administration & dosage (3361) 3361
neoplasm staging (3359) 3359
doxorubicin (3333) 3333
drug delivery systems (3302) 3302
survival (3194) 3194
aged, 80 and over (3174) 3174
antineoplastic agents - therapeutic use (3130) 3130
expression (3033) 3033
antineoplastic agents, phytogenic - administration & dosage (2983) 2983
drug administration schedule (2982) 2982
cisplatin - administration & dosage (2981) 2981
antineoplastic agents (2960) 2960
antineoplastic agents, phytogenic - pharmacology (2946) 2946
breast neoplasms - pathology (2939) 2939
antineoplastic agents - pharmacology (2928) 2928
drugs (2913) 2913
carcinoma, non-small-cell lung - drug therapy (2902) 2902
disease-free survival (2854) 2854
metastasis (2848) 2848
prognosis (2759) 2759
dose-response relationship, drug (2709) 2709
in-vitro (2695) 2695
antimitotic agents (2678) 2678
antineoplastic agents, phytogenic - therapeutic use (2629) 2629
apoptosis - drug effects (2553) 2553
gemcitabine (2530) 2530
drug therapy (2526) 2526
time factors (2509) 2509
combination (2475) 2475
health aspects (2414) 2414
biochemistry & molecular biology (2382) 2382
retrospective studies (2378) 2378
medicine & public health (2377) 2377
cancer therapies (2359) 2359
cardiac & cardiovascular systems (2317) 2317
survival rate (2312) 2312
obstetrics & gynecology (2309) 2309
antineoplastic agents - administration & dosage (2209) 2209
paclitaxel - analogs & derivatives (2200) 2200
breast-cancer (2187) 2187
ovarian neoplasms - pathology (2158) 2158
paclitaxel - chemistry (2158) 2158
deoxycytidine - analogs & derivatives (2153) 2153
combined modality therapy (2152) 2152
surgery (2146) 2146
taxoids (2141) 2141
survival analysis (2139) 2139
antineoplastic combined chemotherapy protocols - administration & dosage (2131) 2131
cells (2101) 2101
drug resistance, neoplasm (2079) 2079
chemistry, multidisciplinary (2047) 2047
lung neoplasms - pathology (2033) 2033
clinical trials (2000) 2000
cell biology (1998) 1998
cell survival - drug effects (1994) 1994
toxicity (1993) 1993
follow-up studies (1962) 1962
phase-ii (1952) 1952
neoplasms - drug therapy (1905) 1905
bevacizumab (1899) 1899
phase-ii trial (1880) 1880
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (50302) 50302
Japanese (1206) 1206
Chinese (591) 591
French (399) 399
German (317) 317
Korean (164) 164
Spanish (134) 134
Russian (94) 94
Portuguese (80) 80
Italian (67) 67
Polish (43) 43
Hungarian (28) 28
Czech (25) 25
Dutch (15) 15
Turkish (15) 15
Danish (5) 5
Hebrew (5) 5
Swedish (5) 5
Lithuanian (4) 4
Finnish (3) 3
Slovak (3) 3
Croatian (2) 2
Slovenian (2) 2
Bulgarian (1) 1
Norwegian (1) 1
Persian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American Heart Association, ISSN 2047-9980, 2018, Volume 7, Issue 24, p. e011245
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 02/2013, Volume 166, Issue 1, pp. 66 - 74
The performance and safety of current antineoplastic agents, particularly water-insoluble drugs, are still far from satisfactory. For example, the currently... 
N-(2-hydroxypropyl)methacrylamide (HPMA) | Biodegradable multiblock copolymer | Paclitaxel | Ovarian cancer | MOLECULAR-WEIGHT | N-(2-hydroxypropyl)methactylamide (HPMA) | CANCER | CHEMISTRY, MULTIDISCIPLINARY | OVARIAN-CARCINOMA | CHEMOTHERAPY | TARGETING DELIVERY | N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMERS | BODY DISTRIBUTION | CONJUGATE | PHARMACOLOGY & PHARMACY | IN-VIVO EVALUATION | CREMOPHOR EL | Molecular Weight | Nanoparticles - chemistry | Paclitaxel - chemical synthesis | Biocompatible Materials - chemistry | Humans | Ovarian Neoplasms - pathology | Acrylic Resins - chemical synthesis | Paclitaxel - pharmacokinetics | Drug Carriers - chemistry | Biocompatible Materials - chemical synthesis | Tissue Distribution | Paclitaxel - chemistry | Antineoplastic Agents, Phytogenic - administration & dosage | Acrylic Resins - pharmacokinetics | Female | Antineoplastic Agents, Phytogenic - therapeutic use | Paclitaxel - administration & dosage | Antineoplastic Agents, Phytogenic - pharmacokinetics | Ovarian Neoplasms - drug therapy | Cell Survival - drug effects | Paclitaxel - analogs & derivatives | Drug Carriers - chemical synthesis | Acrylic Resins - chemistry | Paclitaxel - therapeutic use | Acrylamides - chemistry | Xenograft Model Antitumor Assays | Acrylic Resins - therapeutic use | Animals | Mice, Nude | Cell Line, Tumor | Mice | Acrylamides - chemical synthesis | Drugs | Drug delivery systems | Dosage and administration | Vehicles | Index Medicus | Ascites | paclitaxel | biodegradable multiblock copolymer | ovarian cancer
Journal Article
Journal of clinical pharmacology, ISSN 0091-2700, 2014, Volume 54, Issue 10, pp. 1097 - 1107
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 07/2015, Volume 9, pp. 3767 - 3777
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 3/2008, Volume 108, Issue 2, pp. 241 - 250
Journal Article
Expert Opinion on Pharmacotherapy, ISSN 1744-7666, 2006, Volume 7, Issue 8, pp. 1041 - 1053
Journal Article
ACS Nano, ISSN 1936-0851, 04/2015, Volume 9, Issue 4, pp. 3540 - 3557
Recently, a commercial albumin-bound paclitaxel (PTX) nanocarrier (Abraxane) was approved as the first new drug for pancreatic ductal adenocarcinoma in almost... 
SUPPORTED MEMBRANES | paclitaxel | PHYSICAL-PROPERTIES | synergy | mesoporous silica nanoparticle | VIVO | NAB-PACLITAXEL | MATERIALS SCIENCE, MULTIDISCIPLINARY | CHEMISTRY, PHYSICAL | NANOSCIENCE & NANOTECHNOLOGY | MODEL | CYTIDINE DEAMINASE | CHEMISTRY, MULTIDISCIPLINARY | OVERCOME DRUG-RESISTANCE | co-delivery | pancreatic cancer | IN-VITRO | ratiometric | gemcitabine | BILAYERS PROTOCELLS | NANOTECHNOLOGY | Albumins - chemistry | Deoxycytidine - chemistry | Paclitaxel - pharmacology | Pancreatic Neoplasms - metabolism | Nanoparticles - chemistry | Humans | Deoxycytidine - pharmacology | Antineoplastic Agents - therapeutic use | Drug Carriers - chemistry | Pancreatic Neoplasms - drug therapy | Albumins - therapeutic use | Paclitaxel - chemistry | Deoxycytidine - therapeutic use | Female | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Pancreatic Neoplasms - pathology | Silicon Dioxide - chemistry | Antineoplastic Agents - chemistry | Paclitaxel - therapeutic use | Drug Synergism | Albumins - pharmacology | Animals | Cell Transformation, Neoplastic | Cytidine Deaminase - metabolism | Cell Line, Tumor | Mice | Lipid Bilayers - chemistry | Porosity | Deoxycytidine - analogs & derivatives | Index Medicus | Drugs | Effectiveness | Metabolites | Biocompatibility | Lipids | Nanostructure | Tumors | Cancer
Journal Article
Pharmaceutical research, ISSN 1573-904X, 2014, Volume 32, Issue 3, pp. 1002 - 1016
Albumin nanoparticles have been explored as a promising delivery system for various therapeutic agents. One limitation of such formulations is their poor... 
Biochemistry, general | Biomedical Engineering | colloidal stability | paclitaxel | Biomedicine | Pharmacy | Medical Law | Pharmacology/Toxicology | pharmacokinetic | liposome | albumin nanoparticle | VITRO | COMPLEX MICELLES | DRUG-DELIVERY | HUMAN SERUM-ALBUMIN | CHEMISTRY, MULTIDISCIPLINARY | POLYMERIC NANOPARTICLES | FORMULATIONS | BOUND PACLITAXEL | PHARMACOLOGY & PHARMACY | POLYETHYLENE-GLYCOL | IN-VIVO EVALUATION | BLOCK-COPOLYMER | Albumins - chemistry | Injections, Intravenous | Paclitaxel - pharmacology | Albumin-Bound Paclitaxel | Humans | Half-Life | Male | Melanoma, Experimental - metabolism | Polyethylene Glycols - chemistry | Paclitaxel - pharmacokinetics | Breast Neoplasms - metabolism | Nanoparticles | Tissue Distribution | Paclitaxel - chemistry | Antineoplastic Agents, Phytogenic - administration & dosage | Lipids - chemistry | G2 Phase Cell Cycle Checkpoints - drug effects | MCF-7 Cells | Female | Paclitaxel - administration & dosage | Antineoplastic Agents, Phytogenic - pharmacokinetics | Nanomedicine | Cell Survival - drug effects | Drug Stability | Solubility | Melanoma, Experimental - pathology | Antineoplastic Agents, Phytogenic - chemistry | Technology, Pharmaceutical - methods | Chemistry, Pharmaceutical | Particle Size | Animals | Breast Neoplasms - pathology | Mice | Mice, Inbred BALB C | Liposomes | Antineoplastic Agents, Phytogenic - pharmacology | Thin films | Chemotherapy | Analysis | Paclitaxel | Albumin | Drugstores | Dielectric films | Chromatography | Cancer | Proteins | Drug delivery systems | Pharmaceutical sciences | Tumors
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 12/2012, Volume 6, pp. 371 - 384
The taxanes (paclitaxel and docetaxel) represent an important class of antineoplastic agents that interfere with microtubule function leading to altered... 
Taxane analogs | New antimicrotubule agents | Taxane(s) | Novel taxanes | New taxane formulations | CHEMISTRY, MEDICINAL | GYNECOLOGIC-ONCOLOGY-GROUP | POLYMERIC MICELLAR PACLITAXEL | PRIMARY PERITONEAL CANCER | new antimicrotubule agents | ADVANCED PANCREATIC-CANCER | CELL LUNG-CANCER | PHASE-III TRIAL | taxane analogs | new taxane formulations | IXABEPILONE PLUS CAPECITABINE | taxane(s) | ALBUMIN-BOUND PACLITAXEL | METASTATIC BREAST-CANCER | PHARMACOLOGY & PHARMACY | novel taxanes | DOCOSAHEXAENOIC ACID-PACLITAXEL | United States | Humans | Paclitaxel - adverse effects | Antineoplastic Agents - therapeutic use | Drug Approval | Antineoplastic Agents - administration & dosage | Paclitaxel - therapeutic use | Neoplasms - drug therapy | Taxoids - administration & dosage | Taxoids - therapeutic use | Antineoplastic Agents, Phytogenic - administration & dosage | Antineoplastic Agents - adverse effects | Drug Design | Antineoplastic Agents, Phytogenic - therapeutic use | Neoplasms - pathology | Paclitaxel - administration & dosage | Taxoids - adverse effects | United States Food and Drug Administration | Antineoplastic Agents, Phytogenic - adverse effects | Antimitotic agents | Drugs | Care and treatment | Patient outcomes | Analysis | Product/Service Evaluations | Research | Antineoplastic agents | Cancer | Regulatory agencies | Toxicity | Mitosis | Lung cancer | Bladder | Yew | Taxane | Allergic reactions | Neuropathy | Drug resistance | Analogs | Paclitaxel | Needles | Myelosuppression | Gastric cancer | Taxotere | Formulations | Solvents | Evergreen trees | Squamous cell carcinoma | Sarcoma | Taxol | Hypersensitivity | Breast cancer | Pharmacology | FDA approval | Esophagus | Polyoxyethylene sorbitan monooleate | Organic chemistry | Chemotherapy | Dilution | Side effects | Cell death | Reagents | Head and neck cancer | Solid tumors | Taxanes | Prostate cancer | Epothilones | Prostate
Journal Article
Circulation, ISSN 0009-7322, 09/2017, Volume 136, Issue 12, pp. 1102 - 1113
Journal Article